Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202168 | 0.86 | TLR7 (0.42) | TLR7TLR8NUDT1 | |
| SCHEMBL1773379 | 0.73 | TLR7 (0.40) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL1775273 | 0.73 | TLR7 (0.40) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL4520678 | 0.72 | PDE10A (0.34) | — | |
| SCHEMBL203469 | 0.71 | TLR7 (0.44) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL202388 | 0.71 | TLR7 (0.44) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL205116 | 0.71 | TLR7 (0.44) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL2087126 | 0.69 | TLR7 (0.45) | TLR7TLR8 | |
| SCHEMBL10237186 | 0.69 | TLR7 (0.44) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL1773813 | 0.69 | TLR7 (0.44) | TLR7TLR8NUDT1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | IL2, IFNG, IL4 | TLR7 69/4885TLR8 217/4885NUDT1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.